Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3048]

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced...

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )

Checkmate 227: Final analysis for the non small cell lung cancer trial

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Checkmate 227: Final analysis for the non small cell lung cancer trial ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

PARP inhibitors for metastatic breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of...

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )

Association between tTMB and clinical outcomes with pembrolizumab alone in PD...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first...

Dr Thomas Yau - The University of Hong Kong, Hong Kong

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with...

Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advanced gastrointestinal stromal tumours ( Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA )

Using PARP inhibitors to improve quality of life for patients with metastatic...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer